Overview

GYNecological Cancers Treated With NETrin mAbs in Combination With Chemotherapy and /or Pembrolizumab

Status:
Recruiting
Trial end date:
2024-11-25
Target enrollment:
Participant gender:
Summary
The aim of this study is to investigate the safety and the clinical activities of NP137 when combined with pembrolizumab and/or chemotherapies in patients with advanced/metastatic gynecological cancers (2 types: endometrial carcinoma and cervix carcinoma).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
NETRIS Pharma
Collaborators:
Centre Leon Berard
Merck Sharp & Dohme Corp.
Treatments:
Carboplatin
Paclitaxel
Pembrolizumab